Oncology company One-carbon Therapeutics has entered a strategic collaboration with precision medicine company Tempus AI to advance precision oncology development.  The collaboration will leverage Tempus’ proprietary, de-identified multimodal database and bioinformatics knowledge to advance molecular insights supporting the clinical development of TH9619.  TH9619, developed by One-carbon Therapeutics, is a first-in-class, potent small-molecule inhibitor of overexpressed […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!